Equity
€288,316 from €574,829 in 2017
Equity fell by 50% in 8 years.
MILLENIUM PHARMA
Lifetime
20 annual accounts with figures on one time axis, 26 filings since 2000peak €476,023 (2019)
€423,867▼ 6.1%
peak €261,358 (2019)
€105,304▼ 17.7%
peak €574,829 (2017)
€288,316▲ 1.9%
€859,686▲ 12.4%
peak 4.6 FTE (2021)
4.3 FTE▼ 2.3%
Board2 names since 2021
1 directorAK Herbo Pharma
Owners
100%AK Herbo Pharma
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Dividend €30,000
Key points
from the 2025 annual accountsChecked score
85
Excellent
Financially stronger than 50% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025lowest value
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025
08-2025: 0.4%▲ +0.2 percentage points vs 07-2025
09-2025: 0.2%▼ -0.2 percentage points vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.7%▲ +0.4 percentage points vs 07-2026highest value
09-2026: 0.4%▼ -0.3 percentage points vs 08-2026
10-2026: 0.4%● unchanged vs 09-2026
11-2026: 0.4%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Last filed accounts filed 31 days late; 1 of the last 3 accounts late
Sector: Retail trade (NACE 47)
lowers risk
Founded in 1999
Size: 4.3 FTE, total assets €1.1m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 41% of them on solvency, 44% on liquidity, 72% on profitability and 45% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,818 companies had the same profile as MILLENIUM PHARMA has now. Each dot stands for 10 companies, two years later.
95.1%
were still trading
3.7%
stopped another way
1.0%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of MILLENIUM PHARMA itself: 0.4% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,818 companies, not a prediction for MILLENIUM PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €24,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.53 (1.71 in 2024), above the usual 1.5. Short-term debt is 43.5% and cash 13% of total assets. However, 74.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €288,316
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
31 days late
2024
20 days late
2023
23 days late
2022
46 days early
2021
6 days early
2020
4 days early
2019
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 7 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 20 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- AK Herbo Pharma 100%score 55equity €466,258 (2025) · 2025 annual accounts of AK Herbo Pharma
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0467724694
1 director appointed, 1 resignation
Resignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae · Gazette deed
1 director appointed, 1 resignation
Resignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae · Gazette deed
Capital decrease of €297,519.30 to €18,592.01
Capital from €316,111.31 to €18,592.01 · General meeting of 31-07-2018 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MILLENIUM PHARMA Ganshoren | €1.1m | €423,867 | 25.1% | 4.3 |
| APOTHEEK PHARMAGO Nazareth-De Pinte | €1.2m | €436,367 | 30.6% | 4.6 |
| APOTHEEK ST-JORIS Tielt-Winge | €1.1m | €396,044 | 6.4% | 4.1 |
| Pharmacie Des Trois Tilleuls Watermael-Boitsfort | €1.0m | €499,060 | 38.7% | 3.7 |
| Pharmacie Tilman Assesse Assesse | €1.1m | €362,166 | 9.1% | 4 |
| LOMA PHARMA Izegem | €1.2m | €420,865 | 31.2% | 3.9 |
| PHARMACIE LIPPINOIS Brunehaut | €1.4m | €423,532 | 30.2% | 4 |
These companies have the same main activity as MILLENIUM PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1m and €1.4m, founded between 1999 and 2003.
Official details
Source: KBO- Status
- Active since 30-11-1999Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.093.980.0751083 Ganshoren, since 14-09-2000
- Financial year end
- 31 December
- Peppol
- Reachable since 11-12-2025
Annual accounts 2025
- ≈ €1.5mestimated
- €1.1m▲ 9.5%
- Employeeson 31-12-2025
- 4▼ 20.0%
- Filing
- Filed on 31-08-2026
Insights on MILLENIUM PHARMA
MILLENIUM PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €178,837 in 2006 to €423,867 in 2025.
AK Herbo Pharma holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MILLENIUM PHARMA
- What is the company number of MILLENIUM PHARMA?
- The company number of MILLENIUM PHARMA is 0467.724.694. The VAT number is the same number with BE in front: BE 0467.724.694.
- Where is MILLENIUM PHARMA based?
- The registered office is at Van Overbekelaan 153, 1083 Ganshoren.Company details
- What does MILLENIUM PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of MILLENIUM PHARMA?
- MILLENIUM PHARMA is a private limited company (pre-2019) (BVBA).
- When was MILLENIUM PHARMA founded?
- MILLENIUM PHARMA was founded on 30-11-1999.
- Is MILLENIUM PHARMA still active?
- Yes, MILLENIUM PHARMA is an active enterprise in the KBO register.
- How many employees does MILLENIUM PHARMA have?
- MILLENIUM PHARMA had an average of 4.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MILLENIUM PHARMA fall under?
- In its 2025 annual accounts, MILLENIUM PHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of MILLENIUM PHARMA?
- The turnover in financial year 2025 is ≈ €1.5m. This figure is estimated from the gross margin of €423,867 and 47 comparable companies (NACE 477). It probably lies between €1.2m and €2.4m.
- Is MILLENIUM PHARMA profitable?
- In financial year 2025, MILLENIUM PHARMA made a profit of €105,304.
- Where can I find the annual accounts of MILLENIUM PHARMA?
- MILLENIUM PHARMA filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MILLENIUM PHARMA due?
- MILLENIUM PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.